hall's iv & institutional pharmacy, inc.

po box 1900
aledo, texas 76008

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 24, 2014

NYS DOS ID#
4549138

County
NEW YORK

Jurisdiction
TEXAS

Registered Agent
NONE

NYS Entity Type
FOREIGN BUSINESS CORPORATION

Name History
2014 - HALL'S IV & INSTITUTIONAL PHARMACY, INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Ryder Trucks Launches Campaign With 'Inc.'
    Tuesday Sep 19, 2017

    "The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."

    Source: Media Post: Social Media & Marketing Daily
  • FDA Cracking Down On “Rogue Online Pharmacies” Accused Of Illegally Selling Prescription Drugs
    By Mary Beth Quirk - Monday Sep 25, 2017

    While you may be tempted to skip the pharmacy and just order prescription drugs online, it could be very dangerous to use any unapproved medications from illicit online pharmacies. That’s why the U.S. Food and Drug Administration — along with its international enforcement superfriends — is taking action against hundreds of sites accused of selling prescription drugs illegally online.The …

    Source: The Consumerist
  • “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
    By Ben Fidler - Wednesday Jun 7, 2017

    Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]

    Source: Xconomy VC, Deals, & Startups Feed
  • Abbvie’s hep C drug pricing threatens Gilead’s dominance
    By Max Nisen - Tuesday Aug 8, 2017

    Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.

    Source: SFGATE.com: Business and Technology News
  • Hockey Hall of Famer Dick Gamble to get ring back
    Monday Jul 24, 2017

    Hockey Hall of Famer Dick Gamble to get ring backPITTSFORD, N.Y. (AP) — A scuba-diving treasure hunter who found an American Hockey League Hall of Fame ring in one of New York's Finger Lakes is returning it to its owner.

    Source: SFGATE.com: Top News Stories
  • Target’s Efforts To Bring Customers Back Are Starting To Pay Off
    By Laura Northrup - Wednesday Aug 16, 2017

    For the last year or so, Target, America’s other national big-box discount store, has been struggling. Its leaders blamed falling sales on shoppers renovating their houses, on lower traffic to pharmacies after they were sold to CVS, and on customers’ general disinterest in shopping. In the last year, Target refocused on fundamentals instead of retail innovations, and …

    Source: The Consumerist